How to Buy Weed in Zurich: Switzerland’s Pilot Programs Meet Banking-City Rules

Zurich runs one of Europe’s most closely studied cannabis experiments. Züri Can is a scientific pilot, authorized under federal law, that lets enrolled Zurich residents buy THC cannabis through pharmacies, cannabis social clubs, and a municipal facility while researchers track the results.

It is not a retail market, and that distinction shapes everything about it. Participation requires residency, an eligibility screening, and an ongoing commitment to research surveys. Visitors cannot join, and buying outside the study remains subject to Swiss narcotics law.

Below you will find how the pilot actually works, the correct version of Switzerland’s possession and consumption rules, what the low-THC CBD market does and does not permit, what the early research does and does not show, and where national legislation currently stands.

• Züri Can is a federally authorized scientific pilot under Article 8a of the Narcotics Act, not a commercial cannabis market. Enrollment requires City of Zurich residency.
• Participant intake began in March 2023, and legal sales began in August 2023. The study has capacity for up to 3,000 participants, with 2,445 authorized to purchase as of the University of Zurich’s July 8, 2026 update.
• Distribution runs through 10 pharmacies, nine active social clubs, and the municipal Drug Information Centre.
• The purchase limit is 10 grams of pure THC per month, with a maximum of two 5-gram packages per day.
• For adults, possession of up to 10 grams of cannabis for personal use is not punishable under Swiss federal law. Consumption remains prohibited and may draw a CHF 100 fixed penalty.
• Cannabis containing less than 1% THC generally falls outside the Narcotics Act, but it is not unregulated. Food, therapeutic-products, tobacco, and advertising rules apply by product category.
• Switzerland is considering a federal Cannabis Products Act. Consultation ended in December 2025, and in May 2026 the National Council’s health committee returned the proposal to a subcommittee for revision. It has not been enacted.

It depends entirely on whether you are enrolled in Züri Can.

• Enrolled Zurich residents. Legal THC cannabis purchases are available through the study’s authorized supply points, within the monthly and daily limits.
• Everyone else. Cannabis containing at least 1% THC remains a controlled narcotic under Swiss federal law. There is no general retail market.
• Possession by adults. Possession of up to 10 grams of cannabis for personal use is not punishable under federal law. This is an important distinction that most guides get wrong.
• Consumption. Remains prohibited and may be punished with a CHF 100 fixed penalty under the applicable fixed-penalty procedure.
• Cultivation, sale, and supply. Criminal offenses outside the pilot framework.
• Providing cannabis to minors. A criminal offense in all circumstances.

The pilot exists to generate data for national policymaking. It does not signal that cannabis is broadly legal in Switzerland.

Switzerland took a different route from both immediate legalization and strict prohibition. Federal authorities authorized scientific pilot programs in 2021 under Article 8a of the Narcotics Act, allowing designated municipalities to distribute THC cannabis while researchers monitor outcomes.

Züri Can distributes through three channel types:

• Pharmacies. Ten locations offering take-home purchases in a clinical retail setting.
• Cannabis social clubs. Nine active non-profit associations offering on-site consumption and a community setting. Züri Can is currently the only Swiss cannabis pilot that includes cannabis social clubs.
• Drug Information Centre. A municipal harm-reduction facility providing cannabis alongside counseling services.

What separates the pilot from a medical program is that participants need no prescription and no qualifying diagnosis. Eligibility turns on existing cannabis use rather than on a medical condition, which is what makes the resulting data relevant to a potential adult-use framework.

Enrollment criteria are strict, and any single disqualification results in rejection.

Requirements:

• Age 18 or older
• Residence in the City of Zurich, documented by an official residence certificate
• Regular cannabis use for more than one year
• Good German language skills
• Willingness to complete regular research surveys, with follow-up online surveys at six-month intervals

Exclusions:

• Pregnancy or breastfeeding
• Employment as a professional driver, including bus, taxi, and train operators
• Non-residents of the City of Zurich, including tourists and residents of other Swiss municipalities
• First-time or non-regular cannabis users
• Medical contraindications, including certain psychiatric diagnoses

The City announced an increase in capacity to a maximum of 3,000 participants on July 14, 2025, with federal authorization granted that same month. The expansion specifically targeted under-represented groups, including women and occasional users.

The official procedure runs through the participant’s chosen supply point rather than through a central office.

1. Confirm eligibility against the criteria above before contacting any supply point.
2. Select a supply point, choosing between a pharmacy, a social club, or the Drug Information Centre based on whether you want take-home purchasing, on-site consumption, or an integrated counseling setting.
3. Register with that supply point to begin the process.
4. Complete eligibility screening, including urine testing to confirm cannabis use and rule out pregnancy.
5. Complete the online questionnaire, which the study documentation describes as taking approximately 45 minutes.
6. Obtain a current City of Zurich residence certificate, which is required in original form.
7. Attend the study ID appointment, bringing an official identity document, the original residence certificate, and the signed consent form. The study ID is then supplied through your outlet.

Processing times are not officially published, so plan for the steps rather than a specific turnaround.

Purchase limits are expressed in pure THC rather than product weight, which means your allowance varies with potency:

• 10 grams of pure THC per month. A product labeled 20% THC reaches the monthly limit at 50 grams of product.
• A maximum of two 5-gram packages per day.
• Cumulative tracking. The digital tracking system enforces limits across all products and supply points.

Products. The City’s current list includes 16 products spanning flower and hash, with flower available from 5% THC upward. Official prices currently range from roughly CHF 7.20 to CHF 9.80 per gram depending on the product. Because the catalogue and prices are updated periodically, participants should check the current official list rather than relying on any published table.

Quality standards. Züri Can products are Swiss-grown, meet the pilot’s organic and contaminant-control requirements, and carry defined THC and CBD concentrations. Current production is handled by licensed Swiss producers holding the required exemptions for producing THC-containing pilot cannabis.

Guidance for participants. Lower-THC and balanced THC-to-CBD products suit people returning to cannabis or managing tolerance, while higher-potency flower and hash reach the monthly limit faster. Supply point staff provide harm reduction counseling, and vaporization is generally preferred over smoking. Herb’s strain guides and cannabis education cover the fundamentals of potency and effects.

The study’s tracking infrastructure serves two purposes: enforcing purchase limits and collecting research data.

• Anonymized records. The City states that study data are encrypted and anonymized.
• No onward sharing. The City states that study data are not passed to other bodies under the study’s data-protection procedures.
• Limit enforcement. Real-time tracking prevents purchases exceeding the monthly THC cap across supply points.
• Swiss data-protection law applies. Switzerland maintains its own federal data-protection regime.

Switzerland’s 1% THC threshold is higher than the 0.3% standard used in the EU and United States, which supports a substantial low-THC market. The legal picture is more layered than “under 1% equals legal.”

• Outside the Narcotics Act, not outside regulation. Cannabis containing less than 1% THC generally falls outside narcotics control, but its manufacture, sale, labeling, advertising, and age restrictions depend on the product category. Federal health authorities have been explicit that low-THC products cannot simply be sold and advertised at will.
• CBD foods require authorization. Swiss food authorities treat cannabinoids such as CBD as novel foods generally requiring authorization before lawful marketing as food. Many CBD products on the market are not compliant.
• Age restrictions apply to some categories. Products covered by Switzerland’s Tobacco Products Act have been subject to a nationwide minimum sales age of 18 since October 1, 2024.
• Different regimes for different formats. CBD oils, smoking products, cosmetics, and medicines are each governed by separate rules.

Visitors should not assume that any CBD edible or oil offered for sale is legally compliant, and low-THC products do not produce the effects associated with the pilot’s cannabis.

The pilots were designed to generate evidence, and the honest summary is that the evidence is still early.

• Volume data is solid. As of the University of Zurich’s July 8, 2026 update, Züri Can had recorded about 122,368 sales totaling roughly 1,040 kilograms of cannabis.
• Market displacement has been estimated, not established. The City’s October 2025 calculation estimated CHF 7.5 million displaced from the illegal market based on 750 kilograms sold at that point. Later figures require their own dated methodology.
• Sourcing has shifted. Federal review supports the conclusion that legal outlets have become the main source for the majority of participants across several pilots, with exact proportions differing by study.
• No major problems observed so far. Early observations across Swiss pilots have not identified major health or public-order problems, and some participants report improvements in well-being.
• Causal conclusions are premature. The federal evaluation cautions that the evidence base remains too limited for robust quantitative conclusions about participant health outcomes, and researchers say it is too early to draw firm causal conclusions about long-term effects.

The program was approved for extension through October 2028. Zurich’s municipal council approved financing in March 2026, with ethics-committee and federal approval following.

Switzerland is considering a federal Cannabis Products Act that could create regulated adult access nationally.

• Consultation. The National Council’s committee adopted a preliminary draft in February 2025, and formal consultation ran from August 29 to December 1, 2025.
• May 2026 decision. The committee voted to continue work on the proposal but returned it to a subcommittee for revision, because consultation responses were divided and a majority of cantons opposed the draft in its then-current form.
• Draft features. The proposal has included home cultivation of up to three plants, sales through licensed non-profit outlets, a THC-linked levy, and cantonal implementation oversight. These are features of a draft, not current law.
• No fixed timeline. The bill has not been enacted, and there is currently no guaranteed referendum or implementation date.

Pilot data, including Züri Can’s, feeds into this legislative process. Herb’s legalization news tracks developments as they happen.

Can visitors join Züri Can? No. Participation requires documented residence in the City of Zurich and an ongoing commitment to research surveys. Tourist participation would compromise research validity and falls outside the federal authorization.

What visitors should understand instead:

• Possession versus consumption. For adults, possession of up to 10 grams for personal use is not punishable, while consumption remains prohibited and may draw a CHF 100 fixed penalty.
• Low-THC products are not a substitute. Products under 1% THC do not produce comparable effects, and compliance varies by product and category.
• Crossing borders is a separate offense. Carrying cannabis into or out of Switzerland is unlawful regardless of what was purchased where. Airport security screening applies in both directions.
• Other Swiss cities differ. Pilot programs operate in several municipalities under their own rules, and none is open to visitors.

European cannabis frameworks differ sharply, and residency is often the deciding factor.

If cannabis access is central to how you travel in Europe, Herb’s Amsterdam cannabis guide covers the region’s most established framework for visitors.

Zurich offers something genuinely unusual, and it is also more constrained than most coverage suggests. Here is how it breaks down:

• A Zurich resident who uses cannabis regularly? Züri Can is worth pursuing. Enrollment runs through your chosen supply point, requires a residence certificate and consent form, and commits you to six-month follow-up surveys.
• Visiting Switzerland? The pilot is closed to you. Understand the possession-versus-consumption distinction and treat low-THC products as a separate category, not a substitute.
• Expecting a dispensary experience? This is a research study with monthly THC caps, daily package limits, and mandatory data contribution. The framing matters.
• Following the reform debate? Consultation on the federal Cannabis Products Act closed in December 2025, and the proposal went back to subcommittee in May 2026. Nothing has been enacted.
• Reading claims about health benefits? Early observations are encouraging on public order and self-reported well-being, and researchers are explicit that the evidence is not yet strong enough for causal conclusions.

For destinations with open legal access, Herb’s cannabis guides cover the full picture.